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Abstract
The coronavirus disease 2019 (COVID-19) pandemic has resulted in significant 
morbidity and mortality since its first case was discovered in December 2019. 
Since then, multiple countries have witnessed a healthcare system collapse due to 
the overwhelming demand for COVID-19 care. Drastic measures have been taken 
globally in order to curb the spread of the virus. However, those measures have 
led to the disruption of other aspects of healthcare, increasing the burden due to 
other medical conditions. We have also stepped back in achieving the ambitious 
goal set in place by World Health Organization to eliminate viral hepatitis as a 
public threat by 2030. Hepatitis B and C are chronic conditions with a significant 
worldwide burden, and COVID-19 has resulted in many hepatitis elimination 
programs slowing or stopping altogether. In this review, we elucidate the impact 
of the ongoing COVID-19 pandemic on the interventions targeted towards the 
elimination of hepatitis B virus and hepatitis C virus. Some of the salient features 
that we have covered in this review include hindrance to screening and diagnostic 
tests, neonatal vaccinations, the transmission dynamics affecting hepatitis B virus 
and hepatitis C virus, role of limited awareness, restrictions to treatment access-
ibility, and disparity in healthcare services. We have highlighted the major issues 
and provided recommendations in order to tackle those challenges.
Key Words: COVID-19; Chronic hepatitis; Review literature; Vaccine; World Health 
Organization; Pandemics
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Core Tip: There has been a multi-fold impact of the pandemic on viral hepatitis 
elimination strategies. Due to supply chain disruptions, hepatitis B virus vaccination 
campaigns have been halted. Increased preference for home deliveries, poor antenatal 
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care, and unavailability of at-birth hepatitis B virus vaccine has increased the risk of 
vertical transmission. With needle-sharing activities on the rise and closure of harm 
reduction centers, the spread of blood-borne infections including the hepatitis C virus 
has risen. Hospitals are either being avoided due to the fear of contracting severe acute 
respiratory syndrome coronavirus 2 or are being converted into coronavirus treatment 
wards, resulting in poor management of patients.
Citation: Rehman ST, Rehman H, Abid S. Impact of coronavirus disease 2019 on prevention 




In December 2019 the first case of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) was isolated and identified in Wuhan, China[1]. The coronavirus 
disease 2019 (COVID-19) pandemic that ensued, has led to 2.47 million deaths as of 
February 21, 2021[2].
This medical emergency shed light upon our fragile healthcare system worldwide 
and its vulnerabilities including the immense vacuum questioning our preparedness 
for the next pandemic[3]. Although we were able to achieve making vaccines in record 
time[4], the impact on human life and our economies are yet to be quantified.
On the other hand, hepatitis B virus (HBV) and hepatitis C virus (HCV) have had 
their impact quantified and have been studied for decades. In 2016, the World Health 
Organization (WHO) estimated the prevalence of chronic hepatitis B to be 257 million 
worldwide[5], while it was 71 million for chronic hepatitis C. Chronic hepatitis has a 
worldwide burden that is mostly clinically silent, as it goes undiagnosed in most low 
to middle-income countries (LMICs)[6,7].
We evaluated the sustainable development goals (SDGs) set in place by the WHO 
for the task of eliminating hepatitis B and C as a public health threat by 2030[8]. The 
SDGs include goals such as coverage of three-dose HBV neonatal vaccine, prevention 
of mother-to-child transmission, and harm reduction services such as sterile syringe 
set distribution for people injecting drugs. The efforts done to achieve these 
sustainable goals have been severely compromised due to the current pandemic.
Although it is debatable that having chronic viral hepatitis influences the outcomes 
of having the COVID-19[9-12], worse outcomes with acute respiratory distress 
syndrome in COVID-19 can be expected due to impaired immunity[1,13].
This review elucidates the impact of the COVID-19 pandemic on chronic viral 
hepatitis B and C; since hepatitis A and E contribute relatively less significantly to 
morbidity, mortality, and long-term impact[8]. We evaluated SDGs and current 
existing data in light of them. Some of the salient features, as shown in Figure 1, can be 
identified as a hindrance to screening tests and neonatal vaccinations, the transmission 
dynamics affecting HBV and HCV, the role of limited awareness, restrictions to 
treatment availability, and disparity in healthcare services.
DISRUPTED HEPATITIS B VACCINATION CAMPAIGNS
The COVID-19 pandemic brought in conditions and circumstances that were unusual 
for countries and the world as a whole with factors not previously anticipated. 
Although the rate of hepatitis B vaccinations has been steadily on the rise since the 
1990s, we have learned that geopolitical factors, financial priorities, the image of the 
government, and the health sector have played a huge role in their success or failure
[3]. A recent example within an epidemic can be found in the Ebola outbreak in 2013 in 
West Africa. Due to disrupted vaccination services, limited availability, and allocation 
of funds, a sharp rise in the incidence of measles was reported during the epidemic 
and in the months that followed[14].
The Institute for Health Metrics and Evaluation at the University of Washington 
showcased an overall drop in global vaccination coverage in 2020 to levels as low as 
those seen in the 1990s with words depicting its severity as “… we have been set back 
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Figure 1 This wheel represents, in no particular order or flow, the focal points that give an insight to the impact of coronavirus disease 
2019 on viral hepatitis.
25 years in 25 wk”[15]. High-income countries like the United States had a drop in 
pediatric vaccinations being ordered and administered after an emergency was 
declared on March 13, 2020[16]. Between February and April of 2020, the United 
Kingdom also saw a drop of almost 20% in the administration of measles, mumps, and 
rubella vaccines, as compared to 2019[17].
Reduced availability and provision of HBV vaccines during this COVID-19 
pandemic will have detrimental effects on the incidence of HBV during infancy, 
childhood, and in later years, thus increasing the chances of chronicity in the 
generation to come. This severely impedes our progress to the 2030 elimination goals 
set in place by WHO[8].
Vaccination rates are not in line with the target goals set in SDGs in the LMICs[18], 
and poor screening in the case of viral hepatitis might pose a greater threat in the long 
run compared to the pandemic.
Despite being a high-value investment, vaccines are the most cost-effective way of 
avoiding disease[19]. The decline in measles, mumps, polio, and yellow fever can be 
credited to this. Nothing can truly represent the effectiveness of vaccines other than 
the global eradication of the smallpox virus. This disfiguring disease that had infected 
over 11 million people from 1920 to 1977, was eradicated in 1978 following a world-
wide vaccination campaign.
Although the HBV vaccine is an effective modality, this modality does not exist for 
HCV. Progress has been made on HCV over the past few decades with the year 2020 
being its limelight when Drs. Michael Houghton, Harvey Alter, and Charles Rice were 
awarded the Nobel Prize in Physiology/Medicine for their discovery of the HCV[20]. 
This raises hopes for a cure and even so a vaccine that will be beneficial for the years to 
come. Eliminating HCV as a global threat should be a priority as the disease is present 
actively in 71 million people and accounts for 500000 deaths annually[21,22].
Abbas et al[23] conducted a benefit-risk analysis study in Sub-Saharan Africa during 
the pandemic. The study compared the SARS-CoV-2 pandemic and its impact on 
routine childhood vaccination programs, encompassing several preventable diseases 
including hepatitis B as well as others such as diphtheria, tetanus, pertussis, 
Haemophilus influenzae type b, Streptococcus pneumoniae, rotavirus, measles, meningitis 
A, rubella, and yellow fever. The model found that in a high-impact scenario, for every 
one excess COVID-19 death attributable to SARS-CoV-2 infections acquired during 
routine vaccination clinic visits, 84 deaths in children could be prevented by sustaining 
routine childhood immunization in Africa[23].
HBV vaccination campaigns have also been halted due to disruptions in the supply 
chain. LMICs regions like Pakistan and Sub-Saharan Africa were faced with a shortage 
of HBV vaccines during the pandemic[24,25]. The latter had breakdowns in the cold 
chain and limited financial support from the government[25]. Despite healthcare 
services being ramped up, changes in healthcare-seeking behavior led to a change in 
attitude resulting in reluctance for availing vaccinations[25]. The acceptance and 
readiness of vaccinations are closely linked to the fear of the linked disease and the 
trust placed in the government and its practices[26-28]. Due to heightened misin-
formation on media outlets and a general chaotic atmosphere worldwide, people had 
an anti-science sentiment and heightened distrust in most places[3]. Furthermore, the 
pandemic resulted in increased home-births, which hindered access to vaccines, 
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limiting dosages being given at birth[29].
INTERRUPTION IN THE TRANSMISSION DYNAMICS OF HEPATITIS B 
AND C
The actual numbers to quantify the effects on transmission dynamics in viral hepatitis 
spread are limited[3]. Even though as a result of movement restrictions and 
worldwide lockdowns, the physical spread is expected to decrease, such limiting 
behaviors give rise to risky attitudes on the part of undiagnosed and stable hepatitis. 
Alcohol consumption and unprotected sexual intercourse have increased. Drug abuse 
has been on the rise during the pandemic[30]. Disruption of needle exchange 
programs and harm-reducing services are already scarce in LMICs and with 
lockdowns in place and financial constraints, such limitations would result in cross-
contamination of blood-borne viruses via needles especially HCV[31]. Stowe et al[32] 
reported the closing down of numerous harm reduction service centers in South Africa 
leading to rising in overdose cases in street-based heroin-using individuals. In general, 
the incidence of viral hepatitis will increase by the closing of harm reduction centers
[33].
In Sub-Saharan Africa, liver diseases are highly prevalent although extremely 
underdiagnosed[25]. Being unaware of their viral hepatitis status creates ground for 
increased transmission dynamics in the population that already has limited funding 
for screening, vaccinations, and treatment as a whole. Government efforts will need a 
clear pragmatic strategy as the pandemic progresses to counter such transmission 
dynamics.
The chances of vertical transmission have also increased as the preference for home 
deliveries has surged during the pandemic[29]. There is an increased likelihood of 
missing out on routine HBV and HCV antenatal screening tests. The initial dose of 
HBV vaccine usually administered at birth could either be delayed or skipped. The 
intrapartum administration of hepatitis B immunoglobulin to decrease the vertical 
transmission has also been affected due to home deliveries. These above-mentioned 
limitations all increase the chances of vertical transmission, which will affect a 
generation that is to come, making them highly susceptible to chronic hepatitis due to 
early exposure.
LACK OF AWARENESS PROGRAMS FOR HEPATITIS DURING COVID-19 
PANDEMIC
Lack of awareness is an issue faced by multiple LMICs. Increasing the awareness 
amongst the general population about modes of transmission of viral hepatitis, 
symptoms, screening and diagnosis, management, and follow-up plays an important 
role in elimination programs[34]. Measures taken during the pandemic have led to the 
closure of community-based education and screening programs and in-person events. 
A decrease in voluntary activities such as the NoHep program seems to have 
decreased the diagnosis rate[35].
A lack of information dispersal has been noticed during the pandemic in regards to 
people suffering from viral hepatitis. According to a study conducted by the World 
Hepatitis Alliance, 99 countries were sent a survey to access viral hepatitis services 
during the pandemic. Only 39 (30%) of 131 analyzable responses indicated adequate 
information on COVID-19 had been provided to people living with viral hepatitis in 
their country. One participant from Ukraine said that no specific information had been 
provided for people living with viral hepatitis, although information had been 
provided for people living with human immunodeficiency virus[36].
In low-income countries like Pakistan, new and known cases of HBV and HCV 
patients were compared between January to June of 2020 to the corresponding months 
in 2019. These 23 centers were mostly government-run with free of cost hepatitis 
treatment being provided. All the centers remained open, with no shortage of staff. 
Despite this, the centers still recognized a lesser number of new people coming in for 
treatment; for example, in January 2020 a mean number of 45 new patients registered 
in these centers when there were no cases, while in June 2020, the number has fallen by 
84%[37]. This highlights the lack of awareness amongst individuals regarding the 
seriousness of viral hepatitis.
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IMPAIRMENT IN SCREENING AND DIAGNOSTIC FACILITIES 
One of the most important steps in eliminating viral hepatitis is to screen and diagnose 
in a timely fashion in order to start treatment and prevent transmission. Underdia-
gnosis is a key hurdle in eliminating viral hepatitis, as it can have a long-term impact 
on transmission dynamics.
In 2017, it was estimated that 91% of patients with chronic HBV and 80% of patients 
with chronic HCV had not been diagnosed. In a World Health Alliance survey 
conducted across 32 LMICs, only 36% of the respondents reported that testing services 
were accessible to people. The key issues identified in the survey were either the 
closures or avoidance of testing services[31]. A study revealed that within Sub-Saharan 
Africa, there was a reduction of 71%, 95%, and 83% in the number of patients in the 
hepatitis clinics of Burkina Faso, Tanzania, and the Gambia, respectively, from January 
to April 2020[38]. The primary reason for such a striking decline in the use of 
outpatient services was attributed to the fear of contracting the severe acute 
respiratory syndrome coronavirus 2. Similarly, a decline of 84% in HBV and 74% in 
HCV positive patients coming for a follow-up visit in district hepatitis clinics were 
recorded in Pakistan from January to June 2020[37].
In order to control the pandemic, multiple aggressive measures have been taken 
worldwide, leading to financial disruption of hospitals and healthcare services, often 
resulting in their closures[39]. There have also been shortages in the testing reagents of 
HBV and HCV due to global supply chain disruption. In Italy, a law was enacted in 
February 2020 to conduct graduated birth cohort screening for hepatitis, however, it 
had not been put into action as of May 2020. In Egypt, all the ongoing screening 
programs were also suspended in March 2020, as reported by Blach et al[40] to reserve 
polymerase chain reaction tests for COVID-19; all polymerase chain reaction testing 
for viral hepatitis was halted in Pakistan[37].
REDUCED ACCESS TO TREATMENT FACILITIES FOR CHRONIC 
HEPATITIS
In most countries, travel bans have been enforced, making access to critical care 
difficult. In multiple high-income countries, continuity of care is being maintained by 
utilizing telemedicine services. This has made it convenient for patients to have access 
to remote healthcare. However, in LMICs including Sub-Saharan Africa, telemedicine 
is impractical due to a lack of resources including cell-phones, internet services, and 
modes of payment[25]. The task of generating dedicated phone numbers for gastroen-
terology and hepatology services and spreading awareness regarding telemedicine 
amongst the population is not easily established in communities with a low literacy 
rate. Furthermore, it is difficult for the patients to understand or perform the investig-
ations that the doctor asks them to do.
Even though all the LMICs are not facing or responding to the pandemic in the 
same way, there has been a global negative impact on access to treatment and care. For 
instance, even though a strict lockdown was not imposed in Egypt, HCV management 
centers had a 50% reduction in new patients and follow-ups[40]. A study conducted 
across three clinical sites in the United States, Japan, and Singapore reported a 
significantly decreasing trend in the number of patients who visited liver clinics across 
the three clinical sites during February, March, and April in 2018, 2019, and 2020[41]. 
Although most Spanish harm reduction centers continued to operate during the 
pandemic, there was a reduction in the number of clients using them, which resulted 
in decreased testing and increased discontinuation of ongoing hepatitis C treatment
[42]. A web-based survey conducted in Italy revealed that initiation of HBV and HCV 
treatment was deferred in 23% of the centers, and even in patients considered at high 
risk for serious complications, treatment had been started in only 20%-28% of the cases
[43].
In many countries including Egypt, medications are not manufactured and are 
imported from other countries. Interruption of the supply chain and necessary 
reallocation of healthcare resources has resulted in a remarkable shortage of 
medications for viral hepatitis, as reported by studies conducted in Egypt[44], Sub-
Saharan Africa[38], and Pakistan[37]. In Italy, 26% of the hepatology wards had been 
converted to COVID wards, and 33% had bed reductions[43].
As a result of interrupted and substandard treatment of viral hepatitis, there is an 
increased risk of disease flares that could promote transmission and also increase 
resistance to viral drugs. Routine monitoring of laboratory investigations including 
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liver function tests and complete blood counts were also significantly reduced because 
of increased priority given to COVID tests, as reported by Mustafa et al[37]. This is 
likely going to result in higher rates of severe worse outcomes such as decompensated 
liver disease and hepatocellular carcinoma. Certain reports have suggested that 
medications such as tocilizumab and corticosteroids, which are commonly being used 
to treat COVID-19 infections, can result in the reactivation of dormant HBV infection
[45,46]. This may be an important cause of increased morbidity and mortality in 
patients with a prior HBV infection as a rapid rise in alanine aminotransferase levels 
following viral reactivation can in some cases lead to a fulminant hepatic failure. 
Hence, antiviral prophylaxis against HBV reactivation should be considered[47]. 
Furthermore, it is also recommended that liver tests should be performed routinely in 
all COVID-19 patients, particularly the ones receiving remdesivir and tocilizumab, 
regardless of their baseline values[48].
WIDENING DISPARITIES IN HEPATITIS-RELATED HEALTHCARE
The pandemic is causing health care and socioeconomic inequalities between regions 
and countries. The communities most underserved by the healthcare systems have an 
increased risk of contracting the SARS-COV-2 virus and are more likely to have non-
communicable comorbidities, which further increases the chances of COVID 
associated complications[3,49].
The WHO survey reported that in LMICs, treatment access has been hampered due 
to movement restrictions and suspension of clinical services. Fifty-two percent of the 
frontline health workers from the 32 LMICs reported that treatment was not accessible 
by patients[31]. However, only 8% of the respondents from the United States reported 
an issue with access to treatment. This highlights the discrepancy between high-
income countries and LMICs, the latter suffering from more severe consequences as a 
result of the pandemic[36].
National economies are crumbling and most giants in the varied sectors are 
downsizing to get through the pandemic. This increases the risk for people living in 
countries where universally accessible health care systems are not present, especially 
in rural areas of LMICs like India and Nigeria where daily wage earners are limited to 
healthcare by access and out-of-pocket expenditure for medical facilities[36]. Similar 
cases have also been accounted for in the United States, a high-income country where 
almost 6.2 million people have lost their jobs, thus losing the medical insurance linked 
to their jobs, during the pandemic[50]. Health disparity has affected almost everyone 
in one way or the other but the basic difference lies in access to basic medical help.
Primary care settings and general practitioners, which have an essential role in 
hepatitis elimination, are now focusing on the COVID-19 pandemic and this change 
can further reduce both diagnosis and treatment rates of hepatitis patients. Countries 
with a low number of doctors to population ratio will be affected more[51,52].
OVERCOMING THE CHALLENGES
A pulse survey conducted across 100 countries of five different WHO regions not only 
provided an insight on the extent of healthcare disruption but also listed a few 
strategies that have been adopted by those regions to mitigate the impact of COVID-19 
on essential health services during the pandemic[53]. Based on the approaches that the 
responding countries had implemented to overcome the healthcare disruptions, we 
have come up with a list of recommendations that can be utilized by researchers and 
policymakers to prevent transmission, increase screening and diagnosis, and provide 
prompt management of patients with HBV and HCV, to counter the impact of COVID-
19 pandemic (refer to Figure 2). We can use this crisis as an opportunity to develop a 
healthcare system that is sustainable and does not collapse in case of continued 
morbidity and mortality due to the pandemic.
CONCLUSION
There is no doubt that drastic measures needed to be taken in order to curb the 
pandemic, but as a result of those measures, we might be stepping backward in 
achieving the goal of eliminating viral hepatitis by 2030. There is a dire need to come 
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Figure 2 Overcoming the challenges. This figure addresses possible recommendations and solutions to the coronavirus disease 2019 pandemic crisis that 
has and is affecting our goal of achieving 2030 World Health Organization goal for elimination of chronic hepatitis B virus and hepatitis C virus. HBV: Hepatitis B virus; 
HCV: Hepatitis C virus; RT-PCT: Reverse transcriptase polymerase chain reaction.
up with guidelines that guarantee consistent care of patients with viral hepatitis, in 
case there is another wave of the pandemic. The impact of COVID-19 is going to 
extend beyond just the morbidity and mortality related to that disease. Hence, 
elimination efforts for viral hepatitis must be resumed as soon as possible.
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